Introduction Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder caused by autoantibodies targeting components of the neuromuscular junction, particularly the acetylcholine receptor (AChR). These antibodies impair neuromuscular transmission, resulting in fluctuating muscle weakness and fatigue. While immunosuppressive agents such